Heart Failure in Relation to Anthracyclines and Other Chemotherapies
References
- Di Marco A Cassinelli G Arcamone F The discovery of daunorubicin Cancer Treat Rep 1981 65 Suppl 4 3 8
- Vejpongsa P Yeh ET Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities J Am Coll Cardiol 2014 Sep 2 64 9 938 45
- Swain SM Whaley FS Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 2003 Jun 1 97 11 2869 79
- Henriksen PA Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention Heart 2018 Jun 104 12 971 7
- Von Hoff DD Layard MW Basa P Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 1979 Nov 91 5 710 7
- Giordano SH Lin YL Kuo YF Hortobagyi GN Goodwin JS Decline in the use of anthracyclines for breast cancer J Clin Oncol 2012 Jun 20 30 18 2232 9
- Pinder MC Duan Z Goodwin JS Hortobagyi GN Giordano SH Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer J Clin Oncol 2007 Sep 1 25 25 3808 15
- Oeffinger KC Mertens AC Sklar CA Childhood Cancer Survivor Study Chronic health conditions in adult survivors of childhood cancer N Engl J Med 2006 Oct 12 355 15 1572 82
- Armstrong GT Oeffinger KC Chen Y Modifiable risk factors and major cardiac events among adult survivors of childhood cancer J Clin Oncol 2013 Oct 10 31 29 3673 80
- McGowan JV Chung R Maulik A Piotrowska I Walker JM Yellon DM Anthracycline Chemotherapy and Cardiotoxicity Cardiovasc Drugs Ther 2017 Feb 31 1 63 75
- Steinherz LJ Steinherz PG Tan CT Heller G Murphy ML Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 1991 Sep 25 266 12 1672 7
- Zamorano JL Lancellotti P Rodriguez Muñoz D ESC Scientific Document Group 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J 2016 Sep 21 37 36 2768 801
- Cardinale D Colombo A Bacchiani G Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy Circulation 2015 Jun 2 131 22 1981 8
- Songbo M Lang H Xinyong C Bin X Ping Z Liang S Oxidative stress injury in doxorubicin-induced cardiotoxicity Toxicol Lett 2019 Jun 1 307 41 8
- Doroshow JH Effect of anthracycline antibiotics on oxygen radical formation in rat heart Cancer Res 1983 Feb 43 2 460 72
- Singal PK Iliskovic N Li T Kumar D Adriamycin cardiomyopathy: pathophysiology and prevention FASEB J 1997 Oct 11 12 931 6
- Menna P Salvatorelli E Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview Chemotherapy 2017 62 3 159 68
- Gewirtz DA A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 1999 Apr 1 57 7 727 41
- Eder AR Arriaga EA Capillary electrophoresis monitors enhancement in subcellular reactive oxygen species production upon treatment with doxorubicin Chem Res Toxicol 2006 Sep 19 9 1151 9
- Goffart S von Kleist-Retzow JC Wiesner RJ Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy Cardiovasc Res 2004 Nov 1 64 2 198 207
- Goormaghtigh E Huart P Praet M Brasseur R Ruysschaert JM Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity Biophys Chem 1990 Apr 35 2–3 247 57
- Dresdale AR Barr LH Bonow RO Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy Am J Clin Oncol 1982 Dec 5 6 657 63
- Myers C Bonow R Palmeri S A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine Semin Oncol 1983 Mar 10 1 Suppl 1 53 5
- Iarussi D Auricchio U Agretto A Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma Mol Aspects Med 1994 15 Suppl s207 12
- Minotti G Salvatorelli E Menna P Pharmacological foundations of cardio-oncology J Pharmacol Exp Ther 2010 Jul 334 1 2 8
- Ichikawa Y Ghanefar M Bayeva M Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation J Clin Invest 2014 Feb 124 2 617 30
- Swain SM Vici P The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review J Cancer Res Clin Oncol 2004 Jan 130 1 1 7
- Hardaway BW Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes Curr Opin Cardiol 2019 May 34 3 289 95
- Tewey KM Rowe TC Yang L Halligan BD Liu LF Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 1984 Oct 26 226 4673 466 8
- Lyu YL Kerrigan JE Lin CP Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 2007 Sep 15 67 18 8839 46
- Zhang S Liu X Bawa-Khalfe T Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 2012 Nov 18 11 1639 42
- Torti FM Bristow MR Howes AE Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy Ann Intern Med 1983 Dec 99 6 745 9
- Lipshultz SE Colan SD Gelber RD Perez-Atayde AR Sallan SE Sanders SP Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 1991 Mar 21 324 12 808 15
- Billingham ME Bristow MR Glatstein E Mason JW Masek MA Daniels JR Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation Am J Surg Pathol 1977 Mar 1 1 17 23
- Hasan S Dinh K Lombardo F Kark J Doxorubicin cardiotoxicity in African Americans J Natl Med Assoc 2004 Feb 96 2 196 9
- Chow EJ Chen Y Kremer LC Individual prediction of heart failure among childhood cancer survivors J Clin Oncol 2015 Feb 10 33 5 394 402
- Chow EJ Chen Y Hudson MM Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer J Clin Oncol 2018 Jan 1 36 1 44 52
- Szmit S Jurczak W Zaucha JM Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma J Am Soc Hypertens 2014 Nov 8 11 791 9
- Aminkeng F Bhavsar AP Visscher H Canadian Pharmacogenomics Network for Drug Safety Consortium A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer Nat Genet 2015 Sep 47 9 1079 84
- Linschoten M Teske AJ Cramer MJ van der Wall E Asselbergs FW Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk Circ Genom Precis Med 2018 Jan 11 1 e001753
- Semsei AF Erdelyi DJ Ungvari I ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia Cell Biol Int 2012 Jan 36 1 79 86
- Visscher H Ross CJ Rassekh SR Canadian Pharmacogenomics Network for Drug Safety Consortium Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children J Clin Oncol 2012 May 1 30 13 1422 8
- Vulsteke C Pfeil AM Maggen C Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients Breast Cancer Res Treat 2015 Jul 152 1 67 76
- Visscher H Ross CJ Rassekh SR CPNDS Consortium Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children Pediatr Blood Cancer 2013 Aug 60 8 1375 81
- Bock KW Köhle C UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects Methods Enzymol 2005 400 57 75
- Aminkeng F Ross CJ Rassekh SR CPNDS Clinical Practice Recommendations Group Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity Br J Clin Pharmacol 2016 Sep 82 3 683 95
- Labeit S Kolmerer B Titins: giant proteins in charge of muscle ultrastructure and elasticity Science 1995 Oct 13 270 5234 293 6
- Garcia-Pavia P Kim Y Restrepo-Cordoba MA Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy Circulation 2019 Jul 2 140 1 31 41
- Yu AF Chan AT Steingart RM Cardiac Magnetic Resonance and Cardio-Oncology: Does T2 Signal the End of Anthracycline Cardiotoxicity? J Am Coll Cardiol 2019 Feb 26 73 7 792 4
- Armenian SH Lacchetti C Barac A Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 2017 Mar 10 35 8 893 911
- Yancy CW Jessup M Bozkurt B American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2013 Oct 15 62 16 e147 239
DOI: https://doi.org/10.14797/mdcj-15-4-243 | Journal eISSN: 1947-6108
Language: English
Page range: 243 - 249
Published on: Oct 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2019 Tolulope A. Agunbiade, Raja Y. Zaghlol, Ana Barac, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.